bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C36: Gastric intestinal metaplasia: Epidemiological and demographic characterization in Puerto Rican Hispanics
Authors: Gonzalez-Pons Maria , Cruz-Cruz Jorge J. , Carla Cepero , Valle Alberto Del , Colon Giancarlo , Alicea Kimberly , Rosado Kathia , Cruz-Correa Marcia 
Published: March 2017

Abstract
Background: Gastric intestinal metaplasia (GIM), a key event in gastric carcinogenesis, is the replacement of gastric mucosa by an epithelium that histologically resembles intestinal mucosa. Helicobacter pylori (H. pylori), the most common chronic bacterial infection in humans, is known to be associated with gastric carcinogenesis. Classification of GIM by histological subtype and pattern sets an important goal for proper surveillance measures. Incomplete GIM confers 4- to 11-fold increased risk for gastric cancer. Despite this, there is no previous data available of GIM prevalence and characterization in Puerto Rico (PR). The aim of this study is to determine the prevalence of GIM within the cohort of patients in PR who underwent diagnostic endoscopy for the period of 2012-2014, and to characterize the demographical and clinicopathological profile of individuals with GIM.
Methods: A cross sectional study design using pathology reports of 4,707 endoscopic biopsies with confirmed diagnosis of GIM between 2012-2014 was performed. These reports were reviewed, and the demographic, geographic, and histopathological data provided were analyzed for characterization of this condition. Study characteristics were described using frequency distributions for categorical variables. SPSS version 17 was used for statistical analysis.
Results: Between 2012-2014, the prevalence of GIM was 10.7%, of which 26.9% of cases were positive for H. pylori. GIM was frequently found at incisura angularis and antrum biopsies. Approximately 99.6% and 71.2% of the reviewed pathology reports lack information about GIM histological subtype and pattern.
Conclusion: The prevalence of GIM is difficult to establish due to asymptomatic nature of the lesion, insufficient number of biopsies or inappropriate localization of biopsies. Despite this, the prevalence of GIM in PR appears to be higher than in United States. We observed that pathology reports lack the proper characterization of GIM necessary to provide adequate surveillance.
Citation Format: Maria Gonzalez-Pons, Jorge J. Cruz-Cruz, Cepero Carla, Alberto Del Valle, Giancarlo Colon, Kimberly Alicea, Kathia Rosado, Marcia Cruz-Correa. Gastric intestinal metaplasia: Epidemiological and demographic characterization in Puerto Rican Hispanics. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C36.
Abstract C61: [Advocate Abstract:] PSA Testing: Black Lives Matter - screenings decreases unnecessary deaths
Authors: Coppin Randall 
Published: March 2017

Abstract
Introduction: The US Preventative Services Task Force (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer has been controversial. If theree are excess deaths among black patients, why abandon the one proven screening test? PSA and Black men: The burden of Prostate Cancer falls disproportionately on African American men; the incidence of prostate cancer is almost 60% higher and the mortality rate is two - three times greater in African American men than in Caucasian men. These disparities can be explained by differences in PSA values, socioeconomic status and transformation rate of prostate cancer in black men vs Caucasian men. Because of the greater tumor cell burden, it has been hypothesized that PSA testing at an earlier age for African American men may allow diagnosis of lower risk prostate cancer, potentially reducing disparities between African American and Caucasian men between the ages of 40 and 54. Solutions: According to various reports, community based interventions in barbershops, community centers and churches have been to shown to significantly increase intention to screen. There is also a groundswell of work done in the last 4 years suggesting that screening with PSA across all groups is actually beneficial (as originally thought) Conclusion: As a patient advocate, it is my job to educate and inform the public by attending scientific seminars and spreading the word in community based interventions about the benefits of screening. There is nothing more valuable than a person's life.
Citation Format: Randall Coppin. [Advocate Abstract:] PSA Testing: Black Lives Matter - screenings decreases unnecessary deaths. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C61.
Abstract C86: Distance to free and low cost screening centers and cervical cancer screening behaviors of low income women in New Jersey
Authors: Gardner Michelle L. , Bandera Elisa V. , Jones Beth A. , Demisse Kitaw , Silvera Stephanie AN 
Published: March 2017

Abstract
Racial/ethnic disparities in cancer outcomes have been well documented. Access to Pap testing may account for some of the variation in the racial and socioeconomic differences in cervical cancer outcomes. The rate of Pap testing within the past three years has been shown to vary by both race/ethnicity and by access to medical care. Given this, there has been an increase in the use of GIS to explore and understand cancer screening behaviors. The goal of this analysis was to evaluate and characterize the relationship between geographic proximity to free or low-cost cancer screening facilities and screening behaviors among low-income women in New Jersey using data collected from a cross-sectional survey (N= 459). Address data from 376 participants were geocoded using an ArcGIS address locator, using TIGER road map data as the source, to conduct a distance analysis between participant location and New Jersey Cancer Education & Early Detection (NJCEED) locations, which offer free and low cost screenings based on income. A majority of participants (60.6%) lived less than five miles from the nearest NJCEED location. There was no statistically significant difference in being screened between living &lt;2 miles versus &gt; 8 miles from a NJCEED location (OR = 1.40, 95%CI = 0.60 - 3.26) after adjusting for age, race, transportation, BMI, insurance, and perceived risk. However, when stratified by race, African American women who lived within 2 miles of a screening location were 5.59 times more likely to report being screened compared to women living more than 8 miles away (95% CI = 1.08 - 28.90), although this trend was not statistically significant (p=.06). Distance to free and low cost screening centers were associated with screening behaviors among low income African American women in NJ, but not low income white and Hispanic women, indicating a need for tailored interventions to reach this at risk population.
Citation Format: Michelle L. Gardner, Elisa V. Bandera, Beth A. Jones, Kitaw Demisse, Stephanie AN Silvera. Distance to free and low cost screening centers and cervical cancer screening behaviors of low income women in New Jersey. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C86.
Abstract IA06: [Advocate Abstract:] A Tale of Two Cases
Authors: Lima Mayra A. 
Published: March 2017

Abstract
Breast Cancer is the most common type amongst women and the second leading cause of cancer deaths in the United States. We know from research that the relative 5 year survival rate for women diagnosed with early stage breast cancer is 98% compared to 23% for late stage. Disparities in cancer come in many shapes and forms and research has shown that they can affect outcomes. The three common types of disparities are: low socioeconomic status; cultural issues, and social biases. These are not exclusive of each other, and often appear in combination.
In South Florida we are blessed with a diverse community with Hispanics, African Americans, Native Americans, and people of Caribbean background, creating a rich cultural ambience. These cultures and ethnicities have many common characteristics such as the love and support of family, beautiful music and delicious foods. Unfortunately, they also have a high incidence of low socioeconomic status, high incident of advanced cancer at diagnosis, and high mortality rate from a diagnosis of cancer.
There are important lessons that can be learned from the rich and unique character of breast cancer care in South Florida.
Citation Format: Mayra A. Lima. [Advocate Abstract:] A Tale of Two Cases. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA06.
Abstract IA07: Adherence to oral chemotherapy in children with Acute Lymphoblastic Leukemia
Authors: Bhatia Smita 
Published: March 2017

Abstract
There is persuasive evidence that poor adherence to oral 6MP in children with ALL is prevalent and is associated with relapse. Carefully conducted studies using objective methods to monitor adherence (MEMS Caps) have yielded a critical level of adherence associated with an increased risk of relapse (~95%). These studies have demonstrated that the prevalence of non-adherence (adherence rate &lt;95%) is 44% among children with ALL, and that 47% of the relapses observed among children entering remission in 1st CR are attributable to non-adherence. Vulnerable sub-populations at high risk of non-adherence include: older age (12-21 vs. &lt;12); non-white race/ethnicity (Hispanics, African Americans and Asians); low annual household income/low parental education; household structure (single mother/multiple children); and absence of a routine surrounding pill taking. The most common self-reported reason for missing 6MP doses is forgetting to take medications. On the other hand, the most common facilitator for not missing 6MP doses is parental vigilance. These observations have informed a randomized clinical trial to enhance adherence to oral 6MP; this trial is currently enrolling patients. The comprehensive intervention package consists of a multimedia interactive patient/parent education program (MIPE), and physician-initiated web-based medication scheduling that translates into printed schedules and daily text-message reminders to prompt directly supervised therapy (DST) by the designated parent. We are studying the impact of this intervention package (IP) vs. MIPE alone (Edu) to improve adherence to oral 6MP in children with ALL. This trial is open at 89 sites. Of the 810 patients approached, 478 patients enrolled (participation rate: 59%). We anticipate reaching the target enrollment of 608 by June, 2017, with analyses completed by December, 2017.
Citation Format: Smita Bhatia. Adherence to oral chemotherapy in children with Acute Lymphoblastic Leukemia. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA07.
Abstract IA08: Pharmacogenomics of anticancer agent toxicity in different populations
Authors: Dolan M. Eileen 
Published: March 2017

Abstract
With over 28 million cancer survivors worldwide, there is a heightened awareness of the long-term toxicities resulting from treatment and their impact on quality of life in cancer survivors. Understanding genomic factors contributing to cancer related symptom burden would be highly beneficial to cancer patients. Preclinical studies using HapMap lymphoblastoid cell lines have indicated inter-individual and inter-population differences in cellular sensitivity to chemotherapeutics (as a representation of toxicity). The differences can be explained, to some extent, by variation in: 1) genetics; 2) gene expression and; 3) modified cytosines. Although this preclinical model provides a means to elucidate the genetic, transcriptomic and molecular underpinnings of population differences in sensitivity to chemotherapeutics, lymphoblastoid cell lines do not represent tissues of toxicity (peripheral neurons, kidney, cardiac cells, hair cells). To this end, clinical genome wide association studies (GWAS) of chemotherapeutic toxicity have been conducted. Unfortunately, most patients in these studies have been white subjects of European descent with an under representation of minorities. Since it is known that allele frequencies of polymorphisms within important pharmacogenes differ among different populations, there is a need to perform GWAS in under represented populations. Unfortunately, GWAS in oncology continue to widen the disparity gap because of the lack of knowledge of genetic variants that put minority populations at risk for chemotherapeutic toxicity.
Citation Format: M. Eileen Dolan. Pharmacogenomics of anticancer agent toxicity in different populations. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA08.
Abstract IA35: Community Health Workers Navigating Patient through Clinical Trials
Authors: Ramos-Calderon Jackie 
Published: March 2017

Abstract
The Promotores/Community Health Worker (P/CHW) model has been highlighted as an effective means of promoting healthy communities and addressing health disparities among at-risk groups not only in the United States but globally. In particular, integration of P/CHWs into local government programs has been considered as a viable means for advancing community resilience, preventive care and wellness. P/CHWs navigate vulnerable populations into the health care system in a timely manner, thereby improving health outcomes overall.
Many P/CHWs have experienced system and cultural barriers on a personal level. This firsthand knowledge provides them with the proper tools to help eliminate the barriers that prevent people from accessing quality health care. They have access to information about local resources, are trained in a culturally and linguistically proficient manner on health issues and are able to navigate those needing follow up care. People who are low-income, elderly, racial/ethnic minorities, women and those residing in rural areas endure serious challenges when diagnosed with chronic diseases caused by lack of information and means of communication. P/CHWs are routinely needed to assist communities and organizations with outreach activities (education to screening), and in-reach (navigation from diagnosis through treatment). These same individuals can be trained on clinical research and used as clinical trials navigators. P/CHWs are the answer to addressing the problem of recruitment and retention of underserved populations as participants in clinical trials.
Citation Format: Jackie Ramos-Calderon. Community Health Workers Navigating Patient through Clinical Trials. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA35.
Abstract A28: Challenging new epigenetic vulnerabilities in human metastatic melanoma PDXs
Authors: Bossi Daniela , Cicalese Angelo , Dellino Ivan Gaetano , Luzi Lucilla , Punzi Simona , D'Alesio Carolina , Cavallaro Elena , Minucci Saverio , Pelicci PierGiuseppe , Lanfrancone Luisa 
Published: March 2017

Abstract
Metastatic melanoma is one of the most aggressive cancers, refractory to most of the current therapies in its late stage. Melanoma is characterized by a strong molecular heterogeneity, and patients can be stratified in different subtypes according to genetic alterations. Despite the approval of new targeted drugs, patient treatment produces only partial responses and frequent and rapid relapses, mostly due to increased resistance. Mounting evidence highlights the necessity to better stratify melanomas on the basis of altered molecular pathways and to define new specific and effective tailored therapies. Our main goal is the genetic and functional characterization of metastatic melanomas aimed to generate new predictive and prognostic biomarkers and to identify new potential “druggable” candidates involved in melanoma progression.
We have generated a series of human-in-mouse melanoma models, by xeno-transplantation of a cohort of human melanoma samples in immune-compromised mice. Our patient-derived xenografts (PDXs) faithfully recapitulate the heterogeneity of the original tumors at phenotypic and genetic level. Taking advantage of our model, we performed the first in vivo genetic screen on patient-derived tumors, using metastatic NRAS- and BRAF-mutant melanomas and targeting chromatin genes (~240). Our screens revealed unprecedented numerosity of tumor drivers (~50% of tested genes) and unexpected functional heterogeneity among patients (~60 drivers per tumor; &lt;15% in common). Tumor drivers, however, were not activated by somatic mutations in the same patients. Several genes have been validated in vivo and then characterized in vitro on primary cultures derived from the patients' cells. We analysed underlying molecular mechanisms of one of the identified drivers, the Histone-lysine N-methyltransferase KMT2D, and showed that it promotes tumorigenesis by dysregulating a subset of transcriptional enhancers and genes involved in cell migration.
Citation Format: Daniela Bossi, Angelo Cicalese, Ivan Gaetano Dellino, Lucilla Luzi, Simona Punzi, Carolina D'Alesio, Elena Cavallaro, Saverio Minucci, PierGiuseppe Pelicci, Luisa Lanfrancone. Challenging new epigenetic vulnerabilities in human metastatic melanoma PDXs. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A28.
Abstract B05: Patient-derived GBM tumors versus patient-derived primary cells and GBM cell lines: lessons from microRNA profiling
Authors: Ofek Paula , Dromi Nir , Yerushalmi Noga , Kredo-Russo Sharon , Grossman Rachel , Ram Zvi , Satchi-Fainaro Ronit 
Published: March 2017

Abstract
Glioblastoma multiforme is a very heterogeneous tumor, highly infiltrative, angiogenic and resistant to standard therapeutic intervention. Experimental models currently used in research are mostly based on cancer cell lines, which are grown in culture for many generations and have lost many essential biological characteristics. In consequence, the xenograft tumor models derived from those cells do not maintain genomic and phenotypic characteristics present in the original tumor. It is questionable whether these artificial preclinical models can serve as reliable platforms to select the lead candidate for a novel therapeutic approach.
We utilized miRNA expression patterns to evaluate the clinical relevance of some of the currently available experimental models of GBM, searching for similarities and differences in miRNA expression levels between freshly isolated tumors, patient-derived primary cells and GBM cell lines grown in culture. The study included 22 formalin-fixed paraffin-embedded (FFPE) tumors from glioblastoma resections. Those were divided into two groups of Short Term Survivors (STS, survived up to 3 months from initial diagnosis; n=12) and Long Term Survivors (LTS, survived more than 3 years from initial diagnosis; n=10).We further tested 6 patient-derived primary cells, and 5 ATCC human GBM cell lines widely used in preclinical research. Two of the cell lines included dormant and fast-growing variants previously developed in our laboratory to resemble LTS and STS phenotypes, respectively. Samples were loaded on custom microRNA (miR) arrays, including 2172 known miRNAs (miRBase 19).
We found several miRNAs that were upregulated in the STS samples while others exhibited higher expression levels in the LTS samples.
Both GBM cell lines and patient-derived primary cells exhibited a miRNA profile which was very different from patient samples. Brain miRNAs used as brain markers, such as hsa-miR-124-3p), show relatively low expression levels in both patient-derived primary cells and commercial cell lines but are highly expressed in tumors.
We concluded that GBM experimental models must be reevaluated and pre-clinical findings derived from long-established and commonly used in vitro and in vivo models should be further validated in patient-derived models that are more suitable to evaluate the potential clinical relevance of new therapeutics.
Citation Format: Paula Ofek, Nir Dromi, Noga Yerushalmi, Sharon Kredo-Russo, Rachel Grossman, Zvi Ram, Ronit Satchi-Fainaro. Patient-derived GBM tumors versus patient-derived primary cells and GBM cell lines: lessons from microRNA profiling. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B05.